Pneuma Respiratory

Pneuma Respiratory is a private, pre-revenue platform technology company developing a next-generation pulmonary drug delivery system. Its core innovation is a low-shear, propellant-free aerosol generator capable of producing tunable, high-respirable-fraction droplets, which is designed to protect biologic integrity and enable precise lung targeting. The digitally connected platform aims to address significant limitations in current nebulizers and inhalers, targeting a broad range of therapeutic areas including asthma, COPD, and oncology. With a strong IP portfolio and a manufacturing partnership with Foxconn, Pneuma is positioning itself as an enabling technology partner for pharmaceutical companies.

Advanced aerosol generation platform for pulmonary drug delivery. Features low-shear aerosol generation for biologics, precision droplet control for targeted lung delivery, high respirable fraction (up to 90%), digital breath actuation, and integrated voice guidance/connectivity for adherence.

Pneuma competes in the advanced pulmonary drug delivery space against established nebulizer companies (e.g., Philips, Vectura, Pari) and inhaler manufacturers developing next-generation devices. Its key differentiator is the combination of low-shear delivery for biologics with very high respirable fraction, a claim not broadly matched by current mesh or jet nebulizer technologies.